{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:08:23Z","timestamp":1782623303389,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jdiacomp.2025.108981","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:13:37Z","timestamp":1740471217000},"page":"108981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors\/SGLT-2i"],"prefix":"10.1016","volume":"39","author":[{"given":"Ruoqi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuomin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.108981_bb0005","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal benefits of finerenone: protecting kidney and heart","volume":"55","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0030","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0035","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0040","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/dom.14915","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0045","first-page":"14","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","author":"Lv","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0060","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor Coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0070","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0075","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0080","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0085","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0095","doi-asserted-by":"crossref","DOI":"10.1159\/000339500","article-title":"Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K\/MAPK signalling","volume":"120","author":"Huang","year":"2012","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0100","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00480.2006","article-title":"Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin","volume":"293","author":"Zhang","year":"2007","journal-title":"Am J Physiol-Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0105","first-page":"134","article-title":"Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists","author":"Abedini","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108741","article-title":"Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone","volume":"38","author":"Filardi","year":"2024","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0115","first-page":"68","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy","author":"Yao","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0120","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.2337\/db21-0983","article-title":"PACS-2 ameliorates tubular injury by facilitating endoplasmic reticulum-mitochondria contact and mitophagy in diabetic nephropathy","volume":"71","author":"Li","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0135","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.5114\/aoms.2019.87135","article-title":"Aldosterone nongenomically induces angiotensin II receptor dimerization in rat kidney: role of mineralocorticoid receptor and NADPH oxidase","volume":"15","author":"Sinphitukkul","year":"2019","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0140","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1111\/bph.15708","article-title":"Mineralocorticoid receptor in cardiovascular diseases-clinical trials and mechanistic insights","volume":"179","author":"Bauersachs","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0145","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0155","first-page":"12","article-title":"Nonsteroidal mineralocorticoid receptor antagonist (Finerenone) in cardiorenal disease","author":"Shah","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0160","first-page":"24","article-title":"Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces vascular injury and increases regulatory T-cells: studies in rodents with diabetic and neovascular retinopathy","author":"Jerome","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0165","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41467-017-00751-w","article-title":"Foxp3(+) Tregs are recruited to the retina to repair pathological angiogenesis","volume":"8","author":"Deliyanti","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0170","first-page":"24","article-title":"Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces vascular injury and increases regulatory T-cells: studies in rodents with diabetic and neovascular retinopathy","author":"Jerome","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCRESAHA.108.176008","article-title":"Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology","volume":"104","author":"Wilkinson-Berka","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0180","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41433-019-0568-y","article-title":"Oral medications for central serous chorioretinopathy: a literature review","volume":"34","author":"Fusi-Rubiano","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108411","article-title":"Design and rationale of FINE-REAL: a prospective study of finerenone in clinical practice","volume":"37","author":"Desai","year":"2023","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.kisu.2021.11.008","article-title":"Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts","volume":"12","author":"Epstein","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0200","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0205","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0210","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/hr.2013.74","article-title":"Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist","volume":"36","author":"Sato","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0215","article-title":"The role of aldosterone in the pathogenesis of diabetic retinopathy","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0220","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0225","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: a meta-analysis","author":"Zuo","year":"2019","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.arr.2008.12.002","article-title":"Signaling mechanisms of angiotensin II in regulating vascular senescence","volume":"8","author":"Min","year":"2009","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0235","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","article-title":"Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation","volume":"26","author":"Suzuki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00592-019-01442-2","article-title":"The clinical significance of long non-coding RNA ANRIL level in diabetic retinopathy","volume":"57","author":"Chen","year":"2020","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0245","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2213-8587(14)70256-6","article-title":"Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis","volume":"3","author":"Wang","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213473","article-title":"Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease","volume":"14","author":"Dai","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0265","first-page":"8","article-title":"Comparative study of the effects of GLP1 analog and SGLT2 inhibitor against diabetic cardiomyopathy in type 2 diabetic rats: possible underlying mechanisms","author":"Hussein","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fendo.2020.00190","article-title":"Prospect of sodium-glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0280","doi-asserted-by":"crossref","first-page":"10915","DOI":"10.1007\/s11033-022-07758-7","article-title":"Emerging roles of sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease","volume":"49","author":"Gan","year":"2022","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0285","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose Cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0290","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0295","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1042\/CS20220212","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with type 2 diabetes and chronic kidney disease","volume":"136","author":"Barrera-Chimal","year":"2022","journal-title":"Clin Sci"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0300","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0305","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0310","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0315","article-title":"Glucose transport, transporters and metabolism in diabetic retinopathy","volume":"1870","author":"Zhang","year":"2024","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0320","article-title":"Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1\/2\/cPLA2\/AA\/ROS pathway independent of hypoglycemic","volume":"13","author":"Hu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0325","first-page":"42","article-title":"Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy","author":"Matthews","year":"2022","journal-title":"Biosci Rep"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0330","article-title":"SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db\/db mice","volume":"152","author":"Gong","year":"2022","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0335","first-page":"23","article-title":"The effect of sodium-dependent glucose cotransporter 2 inhibitor tofogliflozin on neurovascular coupling in the retina in type 2 diabetic mice","author":"Hanaguri","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0340","first-page":"10","article-title":"Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes","author":"Luo","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.31083\/j.fbl2804083","article-title":"Comparing and contrasting the effects of the SGLT inhibitors canagliflozin and empagliflozin on the progression of retinopathy","volume":"28","author":"Herat","year":"2023","journal-title":"Front Biosci"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0350","doi-asserted-by":"crossref","first-page":"462","DOI":"10.12659\/AJCR.909708","article-title":"Recovery from diabetic macular edema in a diabetic patient after minimal dose of a sodium glucose co-transporter 2 inhibitor","volume":"19","author":"Yoshizumi","year":"2018","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0355","first-page":"12","article-title":"Sodium-glucose Co-Transporter 2 inhibitors reduce macular edema in patients with diabetes mellitus","author":"Tatsumi","year":"2022","journal-title":"Life (Basel, Switzerland)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0360","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-023-01899-0","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction","volume":"22","author":"Kintscher","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0365","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"M\u00e5rup","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0370","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","article-title":"Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. Results of a randomized controlled trial with Col4a3-\/- mice","volume":"34","author":"Zhu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0375","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","article-title":"Mineralocorticoid receptor antagonism by finerenone attenuates established pulmonary hypertension in rats","volume":"79","author":"Tu","year":"2022","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.jdiacomp.2025.108981_bb0380","article-title":"The role of aldosterone in OSA and OSA-related hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T06:54:58Z","timestamp":1742972098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1056872725000340"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108981","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors\/SGLT-2i","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108981"}}